Abivax Repurchases $90M Royalties, Prices $45M ADS Offering, Extends Runway to Q4 2027
Abivax repurchased $90 million of royalty certificates by issuing 403,347 ADS at $111.57 each and paying $45 million in cash, reducing legacy obligations and improving financial flexibility. The transaction extends cash runway into Q4 2027 and causes approximately 0.5% share capital dilution.
1. Repurchase of Royalty Certificates
Abivax executed a purchase agreement to repurchase $90 million of royalty certificates, paying $45 million in cash on closing and funding the remaining $45 million through an interest-free vendor loan set off by issuing 403,347 American Depositary Shares at $111.57 each.
2. Strengthened Balance Sheet and Runway
By cancelling the repurchased royalty certificates, Abivax simplifies its capital structure, reduces legacy obligations and strengthens its balance sheet, securing funding for ongoing clinical programs and pre-commercial planning through Q4 2027.
3. Minimal Dilution Impact
The issuance of 403,347 ADS represents roughly 0.5% of share capital; a shareholder with 1% before the offering would hold approximately 0.99% afterwards, and the set-off mechanism means the company receives no net cash proceeds from the ADS issuance.